NTLAHealthcare · BiotechnologyThe 19 Wall Street analysts covering Intellia Therapeutics, Inc. hold a median 12-month price target of $17 — +32.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Intellia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Volatility (21): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NTLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +32.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Evercore ISI Group | Upgrade | Outperform | $16 → $24 |
| 16 July 2026 | Wolfe Research | Downgrade | Underperform | $9.00 |
| 16 July 2026 | Wolfe Research | Downgrade | Underperform | — |
| 10 July 2026 | Wedbush | Maintains | Neutral | $12 → $17 |
| 10 July 2026 | Wedbush | Maintains | Neutral | — |
| 16 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 June 2026 | Wedbush | Reiterates | Neutral | — |
| 13 May 2026 | Bernstein | Maintains | Market Perform | — |
| 13 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 May 2026 | Wedbush | Reiterates | Neutral | — |
| 28 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 28 Apr 2026 | Goldman Sachs | Maintains | Sell | — |
| 28 Apr 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 27 Apr 2026 | Baird | Maintains | Neutral | — |
| 27 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 4 Mar 2026 | Jones Trading | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTLA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 7% of US stocks
Cheaper than 40% of US stocks
Cheaper than 75% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Intellia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Intellia Therapeutics announced that on August 1, 2026, it awarded inducement grants to eight new employees under its amended 2024 Inducement Plan, serving as a material inducement to their employment.
Why it matters — NTLA watchers would note that the company is making equity-based grants to attract and hire new talent under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics reported a second-quarter loss that matched analyst estimates, but revenue fell 46.2% as lower Regeneron collaboration revenues weighed on the top line, causing a revenue miss.
Why it matters — NTLA watchers would track this because a significant revenue decline driven by reduced collaboration income from Regeneron could signal weaker partner-funded milestones and affect the company's near-term financial outlook.
Intellia Therapeutics reported that it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Why it matters — This signals continued clinical progress for NTLA's two most advanced pipeline candidates.
Seeking Alpha published the transcript of Intellia Therapeutics' Q2 2026 earnings call, as indicated by the headline. The item simply presents the earnings call transcript content for that quarter.
Why it matters — An NTLA watcher would want to review the transcript for management's discussion of the company's second-quarter 2026 results and outlook.
Intellia Therapeutics reported a Q2 loss of $0.80 per share, in line with the Zacks Consensus Estimate and narrower than the loss of $0.99 per share a year earlier, while lagging revenue estimates.
Why it matters — NTLA watchers would care because the quarterly results show an improving year-over-year loss but a revenue shortfall versus expectations, reflecting the company's latest financial performance.
The 19 Wall Street analysts covering Intellia Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $8 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Intellia Therapeutics, Inc., 10 rate it a Buy, 6 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Intellia Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Intellia Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +32.4% from the last close, and Ticker Nerd's factor model ranks Intellia Therapeutics, Inc. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Intellia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $61 over the next 12 months.
Intellia Therapeutics, Inc. returned +26.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform.
The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Intellia Therapeutics announced that on August 1, 2026, it awarded inducement grants to eight new employees under its amended 2024 Inducement Plan, serving as a material inducement to their employment.
Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform. The company focuses on developing treatments for genetically defined diseases by precisely editing disease-causing genes either directly inside the body (in vivo) or outside the body in patient-derived cells (ex vivo). Its pipeline targets conditions with significant unmet medical need, including transthyretin (ATTR) amyloidosis, hereditary angioedema, sickle cell disease, and various immuno-oncology indications. Intellia Therapeutics Inc. collaborates with major pharmaceutical partners to advance and potentially scale its therapeutic programs, leveraging shared expertise in drug development and commercialization. Operating within the healthcare and biotechnology sector, the company plays a prominent role in the emerging field of gene editing, where its technologies are used to explore one-time, precisely targeted interventions for serious genetic disorders. Intellia Therapeutics Inc. is headquartered in Cambridge, Massachusetts, a key hub for life sciences and biotech innovation.
CEO Dr. John M. Leonard M.D. · 377 employees · United States · https://www.intelliatx.com